MARKET

NVAX

NVAX

Novavax
NASDAQ

Real-time Quotes | Nasdaq Last Sale

4.110
-0.110
-2.61%
Closed 19:52 11/15 EST
OPEN
4.260
PREV CLOSE
4.220
HIGH
4.260
LOW
4.030
VOLUME
665.11K
TURNOVER
--
52 WEEK HIGH
51.60
52 WEEK LOW
4.010
MARKET CAP
109.23M
P/E (TTM)
-0.5775
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of NVAX and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 7 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

NVAX News

  • Edited Transcript of NVAX earnings conference call or presentation 7-Nov-19 9:30pm GMT
  • Thomson Reuters StreetEvents.1d ago
  • Why 2020 could be a make-or-break year for Novavax
  • American City Business Journals.11/08 20:04
  • One Thing To Remember About The Novavax, Inc. (NASDAQ:NVAX) Share Price
  • Simply Wall St..11/08 18:36
  • Novavax's (NVAX) CEO Stan Erck on Q3 2019 Results - Earnings Call Transcript
  • Seeking Alpha - Transcript.11/08 03:50

More

Industry

Biotechnology & Medical Research
+1.25%
Pharmaceuticals & Medical Research
+1.34%

Hot Stocks

Name
Price
%Change

About NVAX

Novavax, Inc. is a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants. The Company operates through developing recombinant vaccines segment. The Company, through its recombinant nanoparticle vaccine technology, produces vaccine candidates to respond to both known and newly emerging diseases. The Company's product pipeline focuses on a range of infectious diseases with vaccine candidates in clinical development for respiratory syncytial virus (RSV), seasonal influenza, pandemic influenza and the Ebola virus (EBOV). The Company's lead adjuvant for human applications, Matrix-M, is in a Phase I/II clinical trial for pandemic influenza H7N9 vaccine candidate. It is also testing Matrix-M in conjunction with its EBOV vaccine candidate in a Phase I clinical trial. It is developing additional pre-clinical stage programs in a range of infectious diseases, including Middle East respiratory syndrome (MERS).
More

Webull offers Novavax, Inc. (NVAX) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.